Citius Oncology (CTOR) Cash & Equivalents (2022 - 2026)

Citius Oncology (CTOR) has reported Cash & Equivalents for 5 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 2350466.07% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (up 2350466.07% YoY), while the FY2025 annual figure was $3.9 million, up 3504282.14% from the prior year.
• Cash & Equivalents retreated to $2.6 million in Q1 2026 per CTOR's latest filing, from $7.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $7.3 million in Q4 2025 and bottomed at $112.0 in Q3 2024.
• Historically, Cash & Equivalents has averaged $1.2 million across 5 years, with a median of $76853.0 in 2023.
• On a YoY basis, Cash & Equivalents climbed as much as 6513695.54% in 2025 and fell as far as 99.66% in 2025.
• Citius Oncology's Cash & Equivalents stood at $289175.0 in 2022, then tumbled by 88.68% to $32746.0 in 2023, then tumbled by 99.66% to $112.0 in 2024, then soared by 6513695.54% to $7.3 million in 2025, then slumped by 63.91% to $2.6 million in 2026.
• Business Quant data shows CTOR's Cash & Equivalents at $2.6 million in Q1 2026, $7.3 million in Q4 2025, and $3.9 million in Q3 2025.